Unraveling the mysteries of drug resistance in melanoma
August 28, 2018
By Neozene

About half of melanoma patients have mutations in BRAF genes, which can be addressed with drugs like Roche’s Zelboraf. But many patients eventually grow resistant to BRAF inhibitors, for reasons that researchers have struggled to determine. A team of researchers at Mount Sinai School of Medicine in New York used the gene editing system CRISPR-Cas9 to discover a biological signature of drug resistance in melanoma—a biomarker that may provide a target for new treatments. It’s a gene called IGFBP2, which touches off an epigenetic process leading to resistance. They published

Read More

FDA fights EpiPen shortage by extending expiration date for some devices
August 21, 2018
By Neozene

The FDA took steps Tuesday to mitigate the shortage of EpiPens by allowing some expired devices for treating life-threatening allergic reactions to remain on the market. The FDA said that after reviewing data, it had decided it can extend the expiration date by four months for specific lots of EpiPens that are expired or close to expiring. “Many patients rely on self-injectable epinephrine products, such as EpiPen, to reverse life-threatening reactions to bee stings or other allergens for either themselves or for their children. We are doing everything we can

Read More

Predicting the risk of heart disease, diabetes and more using millions of gene variants
August 14, 2018
By Neozene

If physicians could predict which of their patients are more likely to develop serious diseases like breast cancer, type 2 diabetes and coronary artery disease, they could offer personalized preventive care that’s only minimally available today. Scientists at the Broad Institute of MIT and Harvard say they’ve developed a genomic screening tool that can predict the risk not only of those three diseases, but also of atrial fibrillation and inflammatory bowel disease. “We’ve known for long time that there are people out there at high risk for disease based just

Read More